Skip to content

Test Retest Reliability of OA and OH

Test Retest Reliability of Offset Analgesia and Onset Hyperalgesia Paradigm

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05487183
Enrollment
74
Registered
2022-08-04
Start date
2022-08-05
Completion date
2024-04-10
Last updated
2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia, Pain, Pain Catastrophizing

Brief summary

The goal of this study is to measure the test retest reliability of offset analgesia (OA) and onset hyperalgesia (OH) across multiple study visits. OA and OH are quantitative sensory tests (QST) thought to measure how the brain modulates pain. This study will use a heat thermode to induce OA and OH in healthy, pain-free volunteers across 3 study visits. Additional QST measures and survey data relevant to pain modulation will be collected. This study lays the foundation required to use OA and OH as tools to measure pain modulation in clinical trials. Following their validation, we anticipate that OA and OH will serve as predictive and therapeutic biomarkers, which will aid both in the development of novel analgesics and in treatment selection leading to the personalization of pain management.

Interventions

BEHAVIORALMedoc cutaneous probe

A computer-controlled probe delivers temperatures to the skin to measure pain, OA, and OH

BEHAVIORALQuantitative sensory testing

Standard methods involving pinprick, pressure, heat, and cold applied to the skin are used to measure sensation and pain

BEHAVIORALComputer tasks

QST and computer tasks are used to measure changes in pain intensity

Sponsors

University of Pittsburgh
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers with no chronic pain issues who can understand the study procedures

Exclusion criteria

* History of chronic pain * Current significant pain disorder * Active ongoing pain every day that is acute or chronic in duration * Recent history of migraine (1 attack in last 24 months) * Lifetime history mood disorders (anxiety, depression, bipolar) or psychotic disorders. * Subjects taking psychotropics (e.g. benzodiazepines, antidepressants), or medications known to affect the autonomic nervous system (e.g. beta-receptor agonists or antagonists) will be excluded. * Cognitive impairment affecting the ability to provide informed consent, understand directions, and participate in study procedures * Uncontrolled or unstable medical disorder preventing participation in study procedures * Pregnancy * Tattoos on forearm * History of brain surgery * Nonambulatory status * Heart problems such as an irregular heart beat or coronary artery disease * Neurological problems such as seizure, fainting spells, recurrent severe headache, stroke, transient ischemic attack * High blood pressure * Severe liver disease * Severe gastrointestinal disease * Chronic severe infectious disease (e.g. HIV/AIDS)

Design outcomes

Primary

MeasureTime frameDescription
Offset analgesia and onset hyperalgesiabaselinePain intensity difference during heat stimuli measured on a 0-100 sliding scale (0 is no pain, 100 is the most intense pain imaginable) at baseline
Test retest reliability of offset analgesia and onset hyperalgesia1 week post baselinePain intensity difference during heat stimuli measured on a 0-100 sliding scale (0 is no pain, 100 is the most intense pain imaginable) at 1 week after baseline
Differences in brain region activation- QST (quantitative sensory tests)baselineDifference in brain region activation (as measured by oxygenated hemoglobin, HbO) between central nervous system inhibition and control stimuli during QST procedures.
Test retest reliability in brain region activation- QST (quantitative sensory tests)1 week post baselineDifference in brain region activation (as measured by oxygenated hemoglobin, HbO) between central nervous system inhibition and control stimuli during QST procedures at 1 week after baseline

Secondary

MeasureTime frameDescription
Questionnaire score- Situational Pain Catastrophizing Scale post testingbaselineStandardized survey score assessing pain perception immediately after QST procedures are completed at each visit. Scores range from 0-24, with higher scores representing more pain catastrophizing.
Questionnaire score- Multidimensional Assessment of Interoceptive Awareness (MAIA) Version 2baselineStandardized survey score of MAIA-2 assessing mindfulness at the start of visit 1. Total scores range from 0-160 with 8 subscales. Higher scores indicate higher levels of mindfulness.
Questionnaire score- Beck Depression Inventory-II (BDI-II)baselineStandardized survey assessing depression at the start of visit 1. Scores range from 0-63. Total score of 0-13 is considered minimal range of depression, 14-19 is mild, 20-28 is moderate, and 29-63 is severe depression.
Differences in resting fNIRS signalingbaselineDifferences in fNIRS resting state connectivity as measured by brain region activation
Questionnaire score- Multidimensional Assessment of Interoceptive Awareness (MAIA) Version 2 post testingbaselineStandardized survey score of MAIA-2 assessing mindfulness after QST measured at all 3 visits. Total scores range from 0-160 with 8 subscales. Higher scores indicate higher levels of mindfulness.
Pain intensitybaselineChanges in pain intensity during quantitative sensory tests and computer tasks measured on a 0-100 sliding scale (0 is no pain, 100 is the most intense pain imaginable)
Questionnaire score- Generalized Anxiety Disorder 2-item (GAD-2)baselineStandardized survey score of GAD-2 assessing anxiety at the start of visit 1. Scores range from 0-6. Higher scores indicate higher likelihood of having GAD.
Questionnaire score- State Trait Anxiety Inventory (STAI) Y1-2baselineStandardized survey score of state trait anxiety inventory Y1 and Y2 assessing anxiety before QST procedures on visit 1 only. State Anxiety Score ranges from 20-80. Trait Anxiety Score ranges from 20-80. Higher scores indicate worse anxiety state and trait symptoms.
Questionnaire score- Pain Catastrophizing Scale (PCS)baselineStandardized survey score assessing pain perception before QST procedures at visit 1 only. Rumination subscale score ranges from 0-16. Magnification subscale score ranges 0-12. Helplessness subscale score ranges from 0-24. Total score can be calculated by summing subscales. Total score ranges from 0-52, with higher scores indicating more pain catastrophizing.
Questionnaire score- STAI Y1 post testingbaselineStandardized survey score of state trait anxiety inventory Y1 assessing anxiety immediately after QST procedures measured at all 3 visits. Higher scores indicate worse anxiety state.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026